Your browser doesn't support javascript.
loading
Long-Term Effect of Home Blood Pressure Self-Monitoring Plus Medication Self-Titration for Patients With Hypertension: A Secondary Analysis of the ADAMPA Randomized Clinical Trial.
Martínez-Ibáñez, Patricia; Marco-Moreno, Irene; García-Sempere, Aníbal; Peiró, Salvador; Martínez-Ibáñez, Lucia; Barreira-Franch, Ignacio; Bellot-Pujalte, Laura; Avelino-Hidalgo, Eugenia; Escrig-Veses, Marina; Bóveda-García, María; Calleja-Del-Ser, Mercedes; Robles-Cabaniñas, Celia; Hurtado, Isabel; Rodríguez-Bernal, Clara L; Giménez-Loreiro, Margarita; Sanfélix-Gimeno, Gabriel; Sanfélix-Genovés, José.
Afiliação
  • Martínez-Ibáñez P; Health Services Research & Pharmacoepidemiology Unit, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (Fisabio), Valencia, Spain.
  • Marco-Moreno I; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Spain.
  • García-Sempere A; INCLIVA Health Research Institute, Valencia, Spain.
  • Peiró S; Health Services Research & Pharmacoepidemiology Unit, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (Fisabio), Valencia, Spain.
  • Martínez-Ibáñez L; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Spain.
  • Barreira-Franch I; INCLIVA Health Research Institute, Valencia, Spain.
  • Bellot-Pujalte L; Health Services Research & Pharmacoepidemiology Unit, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (Fisabio), Valencia, Spain.
  • Avelino-Hidalgo E; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Spain.
  • Escrig-Veses M; Health Services Research & Pharmacoepidemiology Unit, Fundació per al Foment de la Investigació Sanitària i Biomèdica de la Comunitat Valenciana (Fisabio), Valencia, Spain.
  • Bóveda-García M; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Spain.
  • Calleja-Del-Ser M; INCLIVA Health Research Institute, Valencia, Spain.
  • Robles-Cabaniñas C; INCLIVA Health Research Institute, Valencia, Spain.
  • Hurtado I; INCLIVA Health Research Institute, Valencia, Spain.
  • Rodríguez-Bernal CL; INCLIVA Health Research Institute, Valencia, Spain.
  • Giménez-Loreiro M; INCLIVA Health Research Institute, Valencia, Spain.
  • Sanfélix-Gimeno G; INCLIVA Health Research Institute, Valencia, Spain.
  • Sanfélix-Genovés J; INCLIVA Health Research Institute, Valencia, Spain.
JAMA Netw Open ; 7(5): e2410063, 2024 May 01.
Article em En | MEDLINE | ID: mdl-38728033
ABSTRACT
Importance Patient empowerment through pharmacologic self-management is a common strategy for some chronic diseases such as diabetes, but it is rarely used for controlling blood pressure (BP). Several trials have shown its potential for reducing BP in the short term, but evidence in the longer term is scarce.

Objective:

To evaluate the longer-term effectiveness of BP self-monitoring plus self-titration of antihypertensive medication vs usual care for patients with poorly controlled hypertension, with passive follow-up and primary-care nursing involvement. Design, Setting, and

Participants:

The ADAMPA (Impact of Self-Monitoring of Blood Pressure and Self-Titration of Medication in the Control of Hypertension) study was a randomized, unblinded clinical trial with 2 parallel arms conducted in Valencia, Spain. Included participants were patients 40 years or older, with systolic BP (SBP) over 145 mm Hg and/or diastolic BP (DBP) over 90 mm Hg, recruited from July 21, 2017, to June 30, 2018 (study completion, August 25, 2020). Statistical analysis was conducted on an intention-to-treat basis from August 2022 to February 2024.

Interventions:

Participants were randomized 11 to usual care vs an individualized, prearranged plan based on BP self-monitoring plus medication self-titration. Main Outcomes and

Measures:

The main outome was the adjusted mean difference (AMD) in SBP between groups at 24 months of follow-up. Secondary outcomes were the AMD in DBP between groups at 24 months of follow-up, proportion of patients reaching the BP target (SBP <140 mm Hg and DBP <90 mm Hg), change in behaviors, quality of life, health service use, and adverse events.

Results:

Among 312 patients included in main trial, data on BP measurements at 24 months were available for 219 patients (111 in the intervention group and 108 in the control group). The mean (SD) age was 64.3 (10.1) years, and 120 patients (54.8%) were female; the mean (SD) SBP was 155.6 (13.1) mm Hg, and the mean (SD) diastolic BP was 90.8 (7.7) mm Hg. The median follow-up was 23.8 months (IQR, 19.8-24.5 months). The AMD in SBP at the end of follow-up was -3.4 mm Hg (95% CI, -4.7 to -2.1 mm Hg; P < .001), and the AMD in DBP was -2.5 mm Hg (95% CI, -3.5 to -1.6 mm Hg; P < .001). Subgroup analysis for the main outcome showed consistent results. Sensitivity analyses confirmed the robustness of the main findings. No differences were observed between groups in behaviors, quality of life, use of health services, or adverse events. Conclusions and Relevance In this secondary analysis of a randomized clinical trial, BP self-monitoring plus self-titration of antihypertensive medication based on an individualized prearranged plan used in primary care reduced BP in the longer term with passive follow-up compared with usual care, without increasing health care use or adverse events. These results suggest that simple, inexpensive, and easy-to-implement self-management interventions have the potential to improve the long-term control of hypertension in routine clinical practice. Trial Registration ClinicalTrials.gov Identifier NCT03242785.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monitorização Ambulatorial da Pressão Arterial / Hipertensão / Anti-Hipertensivos País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Monitorização Ambulatorial da Pressão Arterial / Hipertensão / Anti-Hipertensivos País/Região como assunto: Europa Idioma: En Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Espanha